SEC Form 4 · accession 0001209191-19-015891
Surface Oncology, Inc. · SURF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jessica Fees
Officer — See Remarks
Period of report
Mar 1, 2019
Accepted (ET)
Mar 4, 2019 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001718108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.27 | Mar 1, 2019 | A | 14,200 | A | — | Mar 1, 2029 | Common Stock | 14,200 | 14,200 | D |
| Stockk Option (Right to Buy)F2 | $4.27 | Mar 1, 2019 | A | 26,000 | A | — | Mar 1, 2029 | Common Stock | 26,000 | 26,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments after November 18, 2018.
- F2The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019.
Remarks
Title: Principal Accounting Officer, Principal Financial Officer